FY2017 EPS Estimation for Nabriva Therapeutics AG – (NBRV) Boosted by Gabelli

FY2017 EPS Estimation for Nabriva Therapeutics AG – (NBRV) Boosted by Gabelli

Nabriva Therapeutics AG – (NASDAQ:NBRV) – Gabelli raised their FY2017 earnings per share (EPS) estimates for Nabriva Therapeutics AG – in a note issued to investors on Tuesday. Gabelli analyst K. Kedra now forecasts that the firm will post earnings per share of ($2.65) for the year, up from their prior forecast of ($3.45). Gabelli also issued estimates for Nabriva Therapeutics AG -‘s FY2018 earnings at ($2.50) EPS, FY2019 earnings at ($1.60) EPS, FY2020 earnings at ($0.80) EPS and FY2021 earnings at $0.45 EPS.

A number of other equities analysts also recently weighed in on NBRV. Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG – in a research report on Tuesday, December 20th. Royal Bank of Canada set a $22.00 price target on Nabriva Therapeutics AG – and gave the stock a “buy” rating in a research report on Tuesday, December 20th. Zacks Investment Research downgraded Nabriva Therapeutics AG – from a “hold” rating to a “sell” rating in a research report on Wednesday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG – in a research report on Monday, February 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Nabriva Therapeutics AG – in a research report on Friday, February 17th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $14.11.

Nabriva Therapeutics AG – (NASDAQ:NBRV) opened at 12.00 on Thursday. The company’s 50-day moving average is $11.18 and its 200-day moving average is $7.48. Nabriva Therapeutics AG – has a 12 month low of $3.52 and a 12 month high of $12.75. The company’s market cap is $326.35 million.

Several large investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP bought a new stake in Nabriva Therapeutics AG – during the third quarter valued at approximately $2,468,000. FT Options LLC increased its stake in Nabriva Therapeutics AG – by 43.1% in the fourth quarter. FT Options LLC now owns 83,055 shares of the company’s stock valued at $494,000 after buying an additional 25,000 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Nabriva Therapeutics AG – during the fourth quarter valued at approximately $103,000. Acuta Capital Partners LLC increased its stake in Nabriva Therapeutics AG – by 21.1% in the fourth quarter. Acuta Capital Partners LLC now owns 706,383 shares of the company’s stock valued at $4,210,000 after buying an additional 122,862 shares during the last quarter. Finally, Novo A S increased its stake in Nabriva Therapeutics AG – by 108.3% in the fourth quarter. Novo A S now owns 2,326,544 shares of the company’s stock valued at $13,866,000 after buying an additional 1,209,884 shares during the last quarter. 42.86% of the stock is owned by institutional investors.

About Nabriva Therapeutics AG –

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Related posts

Leave a Comment